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In the present study, we addressed the question of a putative relevance of Rho proteins in tumour progression by analysing
their expression on protein and mRNA level in breast tumours. We show that the level of RhoA, RhoB, Rac1 and Cdc42
protein is largely enhanced in all tumour samples analysed (n=15) as compared to normal tissues originating from the same
individual. The same is true for
32P-ADP-ribosylation of Rho proteins which is catalysed by Clostridium botulinum exoenzyme
C3. Also the amount of Rho-GDI and ERK2 as well as the level of overall
32P-GTP binding acvitity was tumour-speciﬁc
elevated, yet to a lower extent than Rho proteins. Although the amount of Rho proteins was enhanced in tumours, most of
them did not show changes in rho mRNA expression as compared to the corresponding normal tissue. Thus, elevated gene
expression seems not to be the underlying mechanism of tumour-speciﬁc overexpression of Rho proteins. Sequence analysis
of RhoA, RhoB, RhoC and Rac1 failed to detect any mutations in both the GTP-binding site and effector binding region. By
analysing 450 tumour samples, the amount of RhoA-like proteins (i.e. RhoA, B, C), but not of Rac1, was found to signiﬁcantly
increase with histological grade and proliferation index. Rho protein expression was neither related to p53 nor to HER-2/neu
oncogene status. Expression of rho mRNAs did not show a signiﬁcant increase with histological grade. Overall the data show
that (1) Rho proteins are overexpressed in breast tumours (2) overexpression is not regulated on the mRNA level (3) the
expression level of RhoA-like proteins correlates with malignancy and (4) Rho proteins are not altered by mutation in breast
tumours.
British Journal of Cancer (2002) 87, 635–644. doi:10.1038/sj.bjc.6600510 www.bjcancer.com
ã 2002 Cancer Research UK
Keywords: Rho GTPases; breast tumours; tumour progression; mutation analysis
The Ras homologous (=Rho) subfamily of low molecular mass (Mr
*21 kDa) GTP-binding proteins encompasses RhoA-like (e.g.
RhoA, B, C), Rac and Cdc42 proteins. Among the Rho GTPases,
speciﬁcally RhoA-like proteins have been shown to be ADP-ribosy-
lated by exoenzyme C3 from Clostridium botulinum which leads to
their inactivation (Aktories, 1997). Using this type of analysis as
well as by microinjection of constitutively activated V14RhoA,
the involvement of Rho proteins in the regulation of the organisa-
tion of the actin cytoskeleton has been demonstrated (Chardin et
al, 1989; Paterson et al, 1990; Wiegers et al, 1991). Rho proteins
are reported to be associated with various kinases such as protein
kinase N (PKN) (Watanabe et al, 1996), phosphoinositide-kinase
(Tolias et al, 1995) and Rho binding kinase (Rock) (Leung et al,
1995). The latter inﬂuences the actin cytoskeleton through phos-
phorylation of the myosin light chain (Amano et al, 1996).
Whereas RhoA is thought to interfere mainly with stress ﬁbre
formation, Rac and Cdc42 are believed to regulate the formation
of lamellipodia and ﬁlopodia, respectively (Nobes and Hall, 1995;
Hall, 1998). In addition to their interference with the microﬁla-
mental network, Rho GTPases participate in the regulation of
endocytosis (Lamaze et al, 1996), cell cycle progression (Olson et
al, 1995), differentiation (Fritz et al, 1994a), genotoxic stress-
induced signalling (Coso et al, 1995; Hill et al, 1995; Minden et
al, 1995) and notably also malignant transformation. For example,
transforming potency has been reported for RhoA (Avraham and
Weinberg, 1989; Perona et al, 1993). Both RhoA and Rac as well
as RhoB are essential for Ras-mediated transformation (Khosravi-
Far et al, 1995; Prendergast et al, 1995; Qiu et al, 1995). Further-
more, Rho GTPases interfere with cadherin dependent cell-cell
contacts as well as with integrin function (Laudanna et al, 1996;
Schwarz et al, 1996; Braga et al, 1997). In addition, guanine
exchange factors (GEFs) for Rho GTPases such as Dbl and Tiam
exhibit oncogenic potency (Habets et al, 1994; Yaku et al, 1994;
Michiels et al, 1995; van Leeuwen et al, 1995; Schwartz et al,
1996). As analysed in vivo by a mouse xenograft model system,
it has been suggested that RhoA and RhoC play a central role in
the process of invasion and metastasis (Imamura et al, 2000; Del
Peso et al, 1997; Itoh et al, 1999; Yoshioka et al, 1999; Clark et
al, 2000). As demonstrated by a chip-based method, RhoC is
involved in mediating metastasis of both murine and human mela-
noma cell lines (Clark et al, 2000). Altogether, data available are
indicative of a possible role of Rho GTPases in tumour develop-
ment and progression (Price and Collard, 2001; Schmitz et al,
2000). Yet, studies on human tissues supporting this hypothesis
are largely missing. It is well established that overexpression and
activation of oncogenes or inactivation of tumour suppressor genes
are related to tumour formation, and often they are used as prog-
nostic markers (Bos, 1988; Anderson et al, 1992; Knudson, 1993).
In particular, point mutations or ampliﬁcation of members of the
ras gene family have been found in a variety of human tumours
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www.bjcancer.com(Bos, 1988). However, only very few reports are available so far
dealing with the analysis of Rho expression or Rho mutation in
human tumours (Suwa et al, 1998a; Fritz et al, 1999b; Schnelzer
et al, 2000).
Thus, despite promising in vitro and animal studies (Schmitz et
al, 2000; Price and Collard, 2001), convincing evidence for the
involvement of Rho GTPases in human carcinogenesis in particu-
lar in tumour progression and invasiveness is largely missing. In
the present study we analysed the expression of different types
of Rho GTPases in breast tumours, both on the level of the
protein and mRNA. In order to take into account a possible
interindividual variation in the expression level of Rho, we
compared tumorigenic tissue with the corresponding normal
tissue originating from the same patient. We also addressed the
question of a putative correlation of particular Rho species with
established prognostic breast tumour markers and investigated
whether or not regulatory domains of Rho proteins are affected
by mutations in tumours.
MATERIALS AND METHODS
Materials
Normal and tumorigenic tissues from breast used in the present
study were subjected to pathological consideration (as to histologi-
cal grade, proliferation index (MIB-1), p53 and HER-2/neu status)
before they were used for biochemical analyses. RhoA (number sc-
179, rabbit polyclonal), RhoB (number sc-180, rabbit polyclonal)
and ERK2 (number sc-154, rabbit polyclonal) speciﬁc antibodies
were purchased from Santa Cruz (San Diego, USA), Rho antibody
detecting all RhoA-like species (i.e. RhoA, B and C) was purchased
from BD Transduction Laboratories (number R73920, mouse
monoclonal) (Lexington, USA). The same is true for Rac1 (number
R56220, mouse monoclonal), Cdc42 (number C70820, mouse
monoclonal) and Rho GDI (number R26320, mouse monoclonal)
antibodies. Clostridium botulinum exoenzme C3 was generously
provided by I Just (Hannover, Germany).
Preparation of tissue extracts
Frozen normal and tumorigenic tissues originating from the same
patient were dissected with a microtome. Extraction of proteins
from cut slices was done as described (Fritz et al, 1999b). Soluble
fraction was obtained by centrifugation (10000 g,4 8C, 10 min).
Protein determination was performed according to Bradford (Brad-
ford, 1976). Extracts were frozen in liquid nitrogen and stored at
7808C.
ADP-ribosylation assay
32P-ADP-ribosylation with 25 mg of protein from cytosolic extracts
was performed as described (Fritz et al, 1994b). Reaction products
were separated by 12.5% SDS–PAGE. After Coomassie staining
gels were dried and subjected to autoradiography. For quantitation,
densitometrical analysis was performed. For calculation of relative
level of ADP-ribosylation of tumours, ADP-ribosylation of extracts
from the human breast carcinoma cell line MCF-7 (grown in
DMEM+10% FCS) was set to 1.0.
Western blot analysis
For immunological detection of Rho proteins 30–50 mg of cytoso-
lic proteins were separated by SDS–PAGE (12.5% gel). After wet-
blotting to nitrocellulose, proteins bound to the membrane were
stained with Ponceau S in order to conﬁrm that identical amounts
of protein have been transferred. Expression of Rho GTPases (i.e.
RhoA, RhoB, Rac, Cdc42) and the Rho-regulatory protein Rho
GDI was analysed using the corresponding Rho speciﬁc antibodies
(Santa Cruz and BD Transduction Laboratories). For determina-
tion of RhoA-like proteins an antibody cross-reacting with RhoA,
B and C was used (number R73920) (BD Transduction Labora-
tories). As conﬁrmed by comparative analysis of a panel of
tumour samples this antibody showed identical expression pattern
as a RhoA speciﬁc one (number sc-179) (Santa Cruz). This ﬁnding
supports previous observation that RhoA is the quantitatively
predominant Rho GTPase within the family of RhoA-like GTPases
(Fritz et al, 1995). As described previously, RhoA speciﬁc antibody
(number sc-179; Santa Cruz) does not cross-hybridise with RhoB
protein and the other way around (Fritz et al, 1999a). After incu-
bation with peroxidase coupled anti-rabbit IgG and anti-mouse
IgG, respectively, proteins were visualised by chemiluminescence.
Filters were repeatedly reprobed, whereby ﬁnally, as a loading
control, ERK2 speciﬁc antibody was used. Relative Rho protein
levels were calculated by referring them to the amount of ERK2
protein. As a further control, the expression of Rho proteins in
extract from human breast carcinoma cell line MCF-7 was deter-
mined. Autoradiograms were quantiﬁed by densitometry
(software: Bio Image IQ).
GTP-overlay assay
Membrane proteins (10000 g pellet fraction) were separated by
SDP–PAGE (15% gel) and blotted to nitrocellulose. Afterwards,
proteins were renatured by overnight incubation in buffer contain-
ing 25 mM Tris/192 mM glycine. After 20 min of preincubation in
binding buffer (50 mM Tris (pH 7.5), 0.3% Tween 20, 5 mM
MgCl2,1m M EGTA), a-
32P-GTP (1 mCi ml
71) was added. After
a further incubation period of 90 min at room temperature, ﬁlters
were washed three times for 30 min with binding buffer. Subse-
quently, the level of
32P-GTP binding was visualised by
autoradiography. As a control, GTP-binding capacity of extracts
from MCF-7 cells was determined. Binding activity of tissue
extracts was related to that of MCF-7 cell extract which was set
to 1.0. This assay aimed at examining whether tumorigenic tissue
differs from normal tissue with respect to the overall expression
of GTP binding proteins, not at analysing differences in the expres-
sion level of a single GTPase species.
Analysis of rho mRNA expression
In order to analyse the expression of the diverse Rho species on the
level of the mRNA, total RNA was isolated from breast tissue
samples using the Quiagen RNA extraction kit (Quiagen, Hilden,
Germany). One mg of RNA was used for semiquantitative RT–
PCR analysis (Titan One tube PCR kit, Roche Diagnostics GmbH).
The sequence of the primer pairs for speciﬁc ampliﬁcation of rhoA,
rhoB, rhoC, rac1, Ki-Ras and GDH were the following: rhoA,
(582 bp PCR product): (1) 5'-ATGGCTGCCATCCGGAAGAAA-3'
and (2) 5'-TCACAAGACAAGGCAACCAGA-3'; rhoB, (548 bp
PCR product): (1) 5'-GCGTGCGGCAAGACGTCTG-3' and (2)
5'-TCATAGCACCTTGCAGCAGTT-3'; rhoC, (582 bp PCR
product): (1) 5'-ATGGCTGCAATCCGAAAGAAG-3' and (2) 5'-
TCAGAGAATGGGACAGCCCCT-3'; rac1, (448 bp PCR product):
(1) 5'-CATCAAGTGTGTGGTGGTGGG-3' and (2) 5'-TTACAG-
CACCAATCTCCTTAG-3'; Ki-Ras, (405 bp PCR product): (1) 5'-
AGCCTGTTTTGTGTCTACTGTT-3' and (2) 5'-GAGAGGCCTG-
CTGAAAATG-3'; GDH, (392 bp PCR product): (1) 5'-GTCTT-
CACCACCATGGAGAAGGCT-3' and (2) 5'-CATGCCAGTGAG-
CTTCCCGTTCA-3'. For speciﬁc ampliﬁcation of rac1 splice
variant rac1b (Jordan et al, 1999; Schnelzer et al, 2000) the follow-
ing two sets of primer pairs were used (1) 5'-CATCAAGTGT-
GTGGTGGTGGG-3' and (2) 5'-GGCAATCGGCTTGTCTTTGCC-
3' resulting in PCR product of 274 bp as well as (1) 5'-GGAG-
AAACGTACGGTAAGGAT-3' and (2) 5'-TTACAGCACCAATCT-
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length. Rac1b mRNA expression was analysed by nested PCR of
the rac1 ampliﬁcation reaction. For PCR ampliﬁcation 30 cycles
were performed (annealing condition: 558C, 2 min). PCR products
were separated onto 1.5% agarose gels and visulised by ethidium
bromide staining. Quantitation of PCR products was performed
by use of image analysis software (Multi-analyst; Bio-Rad Labora-
tories, CA, USA). Speciﬁcity of rho ampliﬁcation products (i.e.
rhoA, rhoB, rhoC) was conﬁrmed by diagnostic restriction enzyme
digests using enzymes speciﬁcally cutting a particular rho cDNA
species. Relative rho mRNA expression was calculated by referring
rho mRNA level to that of GDH or Ki-Ras mRNA level.
Sequence analysis
To investigate whether or not mutations of Rho GTPases do occur
in human breast tumours, PCR products were subjected to auto-
mated sequencing (373A DNA Sequencer from ABI). To detect
putative mutational changes in central regulatory domains of
Rho proteins, we focused on sequencing nucleotides 1-285 (AA
1-95), covering the GTP-binding and effector binding domains of
Rho GTPases.
RESULTS
To address the question of putative relevance of Rho proteins in
human carcinogenesis and tumour progression, we compared the
expression of Rho GTPases in tumours from breast with that of
normal tissue originating from the same individual. As representa-
tively shown in Figure 1A for three pairs of non-malignant vs
corresponding malignant tissues, RhoA, RhoB, Rac1 and Cdc42
are overexpressed on protein level in breast tumours. In normal
tissue, the expression of these Rho proteins is hardly or even not
detectable. The latter is true in particular for RhoA and RhoB.
Because RhoC speciﬁc antibody is not available, we were unable
to analyse the expression of this Rho species on the level of the
protein. In contrast to Rho GTPases, the expression of the Rho
regulatory factor Rho-GDI is easily detectable both in tumour
and in the normal tissue. The same is true for ERK2. In Table 1,
relative levels of expression of Rho proteins, Rho-GDI and ERK2
in 15 pairs of normal vs malignant tissue from the same patient
are compiled. In addition to Western blot analysis, we examined
the expression of Rho proteins by means of Clostridium botulinum
C3-mediated
32P-ADP-ribosylation (Rubin et al, 1988; Aktories,
1997). In line with the Western blot data, extracts from breast
tumours showed largely enhanced levels of ADP-ribosylation as
compared with the normal tissues, which displayed only very faint
amounts of ADP-ribosylated Rho proteins (Figure 2A). Since Rho
GTPases belong to the family of Ras-related small GTP binding
proteins, we wished to know whether small GTPases in general
are overexpressed in tumours and whether this happens to a simi-
lar extent as for Rho proteins. To this end we analysed the overall
GTP binding activity of normal and tumorigenic tissue by
performing
32P-GTP overlay assays. These experiments revealed
that the overall GTP binding activity, representing the expression
level of the family of small GTPases as a whole, was enhanced in
the tumours (Figure 2B). However, it is important to note that also
in the non-malignant tissue
32P-GTP binding activity was clearly
detectable. This is in contrast to Rho proteins. Overall, the data
show that Rho GTPases are highly overexpressed on the level of
the protein in breast tumours. Rho-GDI, ERK2 and the overall
expression of
32P-GTP binding proteins is also enhanced in
tumours, yet to a clearly lower level than Rho proteins are.
Obviously, there is a preferential overexpression of Rho GTPases
in breast tumours.
The high level of expression of Rho proteins in tumours raises
the question as to the underlying mechanism. One possibility is
that rho gene expression is elevated in tumours. Therefore, we
investigated rho mRNA expression in normal tissues and tumours
by use of semiquantitative RT–PCR analyses. Relative rho mRNA
amounts were calculated by relating them to the level of GDH or
Ki-ras mRNA. Surprisingly, the tremendous overexpression of Rho
in tumours on the protein level (see Figure 1A) was not reﬂected at
all on the level of the RNA (Figure 3A). We would like to note that
the data representatively shown in Figure 3A and Figure 1A are
obtained from the analysis of identical samples. As shown in Figure
3B, rho mRNA level in tumours was in most cases not different
from that of the corresponding non-malignant tissue. As referred
to either Ki-ras or GDH mRNA levels, about 50–70% of the
tumours showed a similar rho mRNA expression as the normal
counterpart of the same indiviual. Ten to twenty per cent of the
tumours even showed a 450% reduction in rho mRNA level
(i.e. rhoA and rac1). Only for rhoB and rhoC, about 30% of the
tumours exhibited increase in mRNA levels (Figure 3B). Overall,
the data clearly demonstrate that the highly elevated expression
of Rho proteins in breast tumours is not due to an increase in
rho gene expression. The interindividual variability in rho mRNA
expression was rather large, both in normal and malignant tissues
(*4–10-fold) (Figure 3C). With respect to rac1 a splice variant
named rac1b was recently cloned both from colorectal and breast
tumours (Jordan et al, 1999; Schnelzer et al, 2000). Therefore we
additionally investigated mRNA expression of rac1b in normal vs
malignant breast tissue. Rac1b contains a 57 bp insert as compared
to rac1 (Jordan et al, 1999; Schnelzer et al, 2000). Since the rac1
primers used span the region of the rac1b extra exon, rac1b is
co-ampliﬁed by the primer combination we have used for rac1
expression analysis, and therefore rac1b is occasionally detectable
as a second slower migrating band (Figure 3D, right upper part).
To enable a more sensitive detection of rac1b, we performed nested
PCR reactions using two different sets of rac1b speciﬁc primer
pairs (PC-A and PC-B) which result in rac1b speciﬁc ampliﬁcation
products of 274 and 287 bp in length, respectively (Figure 3D).
Comparing normal breast tissue samples with the corresponding
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N1   T1    N2   T2    N3   T3     kDa
RhoA
RhoB
Rac1
Cdc42
Rho-GDI
ERK2
— 24
— 24
— 24
— 24
— 29
— 46
Figure 1 Expression of Rho GTPases in malignant and non-malignant
breast tissue. Each 50 mg of protein isolated from tumorigenic (T1, T2,
T3) and corresponding normal breast tissue (N1, N2, N3) originating from
the same patient was separated by SDS–PAGE and subjected to Western
blot analysis using the antibodies indicated. Shown is the autoradiography.
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as to expression level of rac1b mRNA, we found that in most cases
(i.e. 80%) rac1b is expressed at a very similar level in malignant
and non-malignant tissue (Figure 3D, lower part). Only two of
the tumours investigated showed an enhanced expression of rac1b
mRNA as compared to their normal counterpart (Figure 3D).
On the level of the protein, the interindividual variability of
RhoA, Rac and Cdc42 protein expression in the tumour samples
was about 3–4-fold (Figure 4A). Variability in the expression of
Rho-GDI and ERK2 proteins was much lower (5two-fold)
(Figure 4A). Measuring
32P-GTP binding activity and the extent
of
32P-ADP ribosylation in breast tumours, an interindividual
variability of *3- and 10-fold, respectively, was observed (Figure
4B). To examine whether the variations in the expression level of
Rho proteins in tumours might be related to histological grade,
which is a generally used prognostic clinical parameter, we
analysed the expression of RhoA-like GTPases (using an antibody
cross-reacting with RhoA, B and C), Rac1, Cdc42, Rho-GDI and
ERK2 in each of the six tumours classiﬁed as WHO grade I and
grade III, respectively. As shown in Figure 5, in particular the
amount of RhoA-like protein, but not the expression of Rac1,
Cdc42 or Rho-GDI seems to vary with histological grading
(Figure 5). For example, as compared with MCF-7 cells, grade I
tumours tended to show a reduced expression of RhoA-like
proteins whereas their expression was similar or even enhanced
in grade III tumours. In contrast, expression of Rac1 Cdc42,
Rho-GDI and ERK2 in both grade I and grade III tumours was
similar to that of MCF-7 cells (Figure 5). This initial observation
indicates that among the family of Rho GTPases especially the
expression of RhoA-like proteins might be related to the malig-
nancy of the tumours. To further investigate this, we studied
whether the expression of RhoA-like proteins is related to histolo-
gical and prognostic clinical parameters, including grading (grade
I, II and III), proliferation index (MIB) as well as HER-2/neu
oncogene and p53 status. For control we included Rac1 in these
studies. As an internal reference for quantitation of the amount
of Rho proteins we used ERK2, because this protein showed a
rather low variability in tumours (see Figure 4A). Extensive analy-
sis of more than 50 tumours revealed that only the relative level
of RhoA-like proteins (Rho/ERK2) signiﬁcantly increases with
histological grading from grade I to grade II (P50.05) up to
grade III (P50.001) (Figure 6A). In the case of Rac1, a signiﬁcant
increase in protein amount was only observed from grade I to
grade II progression (P50.05) but not to grade III. Cdc42 expres-
sion level was not signiﬁcantly different between grade I and
grade III tumours (data not shown). Similar data were obtained
on the basis of the proliferation index of tumours as determined
by quantitation of MIB (Ki-67) positive cells (Figure 6B). Whereas
Rac1 protein level was not signiﬁcantly related to proliferation,
highly proliferative tumours (i.e. 420% MIB-1 positive cells)
showed a signiﬁcant increase in the level of RhoA-like proteins
as compared to tumours with low proliferation index (i.e. MIB-
1 55%) (P50.05). The relative amount of RhoA-like proteins
was neither related to HER-2/neu oncogene expression nor p53
mutation (Figure 7). The same is true for Rac1 proteins (data
not shown). Furthermore, the expression level of RhoA was not
related to the hormone (i.e. oestrogen and progesteron) status
of the tumours (data not shown).
Since there was a particularly large variability in the expression
of rhoB and rhoC mRNAs in tumours (see Figure 3C), and having
in mind a previous report indicating that rhoC mRNA expression
is related to malignancy of pancreas tumours (Suwa et al,
1998a), we also examined whether rhoB and rhoC mRNA expres-
sion is related to histological grading. Initial experiments
indicated that both rhoB and rhoC mRNA expression as well as
rac1 expression might vary between GI and GIII tumours, but
not the expression of rhoA (Figure 8A). Yet, although the expres-
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Table 1 Relative expression level of Rho proteins and Rho-regulating
factor Rho GDI in human breast tumours as compared to the normal tissue
originating from the same patient
No of Expression
Factor samples in normal Expression Rel. expression
analysed analysed
a tissues
b in tumours
b in tumours
c
RhoA 15 nd ++ +++
RhoB 15 nd ++ +++
Rac1 15 nd - 0 ++ +++
Cdc42 15 nd - 0 ++ +++
Rho-GDI 15 + ++ ++
ERK2 15 + ++ +
aOne sample means one pair of tumour together with the corresponding normal
tissue from the same patient.
bnd=not detectable; 0=very low; +=low; ++=high.
c+++=450-fold overexpression in tumour as compared to the corresponding
normal tissue. ++=up to 20-fold overexpression in tumour as compared to the
corresponding normal tissue. +=2–5-fold overexpression in tumour as compared to
the corresponding normal tissue.
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B
Figure 2 Comparative analysis of C3-mediated
32P-ADP-ribosylation
and
32P-GTP binding activity of Rho proteins in human breast tumours
as compared to normal tissue. (A)
32P-ADP-ribosylation of Rho proteins
in extracts from tumour and corresponding non-malignant tissue.
Twenty-ﬁve mg of cytosolic protein was
32P-ADP-ribosylated by use of
exoenzyme C3 from C. botulinum as described in Materials and Methods.
Reaction products were separated by SDS–PAGE. Autoradiography was
densitometrically analysed and relative
32P-ADP-ribosylation of tissue ex-
tracts was related to that of MCF-7 cells, which was set to 1.0. Autoradio-
gram of a representative analysis of three sampled pairs is shown in the
upper part of the ﬁgure. N, normal tissue; T, tumour. (B) Analysis of
32P-GTP binding activity of extracts from non-malignant and tumorigenic
breast tissue. Thirty mg of protein was separated by SDS–PAGE (15%
gels). After wet blotting to nitrocellulose and renaturation,
32P-GTP bind-
ing activity was analysed as described in Materials and Methods. Relative
GTP binding activity of extracts from MCF-7 cells was set to 1.0. The auto-
radiogram of a representative analysis is shown in the upper part of the
ﬁgure. N, normal tissue; T, tumour.
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8B), the observed differences were statistically not signiﬁcant.
Furthermore, analysing 21 tumour samples as to the expression
of the rac1 splice variant rac1b, we found that also rac1b mRNA
is expressed at similar levels in all the tumours investigated (data
not shown).
Ras proteins are frequently mutated in a variety of human
tumours. Therefore, in order to obtain data on the relevance of
the Ras-homologous GTPases in the formation and progression
of breast carcinomas, we analysed Rho proteins as to mutational
alterations in tumours. These analyses were performed by sequen-
cing the rho RT–PCR products. We focused on sequencing
nucleotides coding for amino acids 1–95, because within this
region the GTP-binding and effector binding domain of Rho
GTPases is localised. Overall, 9–11 tumours and three normal
tissues were subjected to sequence analysis. Neither constitutive
mutational activation of RhoA, B, C or Rac1 due to V14 muta-
tion (and V12 for Rac1, respectively), nor any amino acid
exchange in their effector binding domain was detectable (Table
2). Obviously, the regulatory domains of RhoA-like proteins and
Rac1 are highly conserved and functional still intact in the malig-
nant breast tissue.
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Figure 3 rho mRNA expression in tumorigenic and normal breast tissue. (A) Total RNA from tumorigenic and corresponding normal tissue from breast
was analysed as to the expression of various rho mRNA species (i.e. rhoA, rhoB, rhoC, rac1) by RT–PCR analysis as described in Materials and Methods. As
internal control expression of Ki-ras and GDH mRNA was determined. N, normal tissue; T, corresponding tumour. (B) Quantitative densitometrical analysis
of relative rho mRNA expression in breast tumours vs normal tissue. Shown is the percentage of tumours showing similar, increased or reduced level of rho
mRNA expression as compared to the corresponding normal tissue of the same individual. Relative expression of rho mRNA species was calculated by
referring rho mRNA amount to that of either Ki-Ras (Ras) or GDH (GDH). Both types of internal reference markers gave the same results. (C) Interindi-
vidual variation in the relative expression of rho mRNAs (rho mRNA/GDH mRNA) in normal and tumorigenic tissues from breast. (D) The upper part of the
ﬁgure shows the results of representative RT–PCR analyses of two different paired samples (normal tissue (N) vs tumorigenic tissue (T)) where rac1b is
clearly detectable (right part) or not (left part) as a co-ampliﬁcation product of the rac1 RT–PCR reaction (Rac1). 1,2, indicates the position of rac1 and
rac1b ampliﬁcation product, respectively. For more speciﬁc and sensitive analysis of rac1b expression (Rac1b), nested PCR was performed using two dif-
ferent types of rac1b speciﬁc primer combinations as described in Materials and Methods (PC-A and PC-B). In the lower part of the ﬁgure the quantitative
evaluation of the expression of rac1b in normal breast tissue vs the corresponding tumorigenic tissue from the same patient (n=11; paired samples) is shown.
Please note that the samples representatively shown under A and D are different from each other.
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Although Rho GTPases have been shown to be required for cellu-
lar functions associated with tumour progression and invasiveness
(Schmitz et al, 2000; Price and Collard, 2001), studies supporting
the role of Rho for carcinogenesis and tumour progression in
patients with cancer are largely missing. In the present study we
aimed at (1) analysing the expression of different members of
the family of Rho GTPases in breast tumours, both on the level
of the protein and the mRNA, (2) establishing whether a correla-
tion between Rho expression and clinically established diagnostic
and prognostic parameters does exist and, (3) investigating
whether or not Rho GTPases are mutationally altered in tumours.
The data show that RhoA, Rac1 and Cdc42 proteins as well as the
level of
32P-ADP-ribosylation are largely enhanced in malignant
tissue from breast as compared with normal tissue originating
from the same patient. Also the amount of RhoB, which has
recently been described to interfere with cytostatic drug resistance
by inﬂuencing apoptotic cell death (Fritz and Kaina, 2000; Liu et
al, 2001), is enhanced in tumours. Moreover, the level of overall
32P-GTP binding activity as well as the amount of Rho-GDI
protein is elevated in tumorigenic tissue, notably yet to a much
lower extent than Rho proteins. In line with a previous report
we also observed the level of ERK2 protein to be elevated in carci-
nomas as compared to the normal tissue (Sivaraman et al, 1997).
As we have shown here, within the group of tumours, ERK2
seems to be equally distributed. Since the non-malignant tissue
also displayed clearly detectable amounts of Rho-GDI, ERK2
and GTP binding activity, but no or only marginal expression
of Rho proteins, the data indicate that breast tumours differ from
the corresponding normal tissue notably in the overexpression of
Rho GTPases.
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Figure 4 Analysis of expression of Rho proteins, ADP-ribosylated proteins and GTP-binding proteins in breast tumour samples. (A) Expression of Rho
proteins (RhoA-like proteins (Rho), Rac1 and Cdc42) and Rho-regulatory factor Rho-GDI in breast tumours was analysed by Western blot analysis. Ad-
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Figure 5 Comparative expression of Rho GTPases in breast tumours of
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mours of grade I and grade III, respectively, were analysed by Western blot
analysis as to the expression of various Rho GTPase, the Rho-regulatory
factor Rho-GDI and ERK2. As a control, extracts from MCF-7 cells were
included.
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British Journal of Cancer (2002) 87(6), 635–644 ã 2002 Cancer Research UKThe ﬁnding of a large overexpression of Rho proteins in breast
tumours raises the question as to the underlying mechanism, in
particular whether this phenomena is due to increase in rho gene
expression. Surprisingly, in most cases (50–70%) tumorigenic
and corresponding normal tissue expressed very similar levels of
rho mRNAs (i.e. rhoA, rhoB, rhoC, rac1). As compared to the
normal tissue, about 10–30% of the tumours revealed either
enhanced levels of rhoB and rhoC mRNA or even reduced levels
of rhoA and rac1 mRNA. Recently rac1 mRNA expression was
reported to be enhanced in malignant vs benign breast tissues
(Schnelzer et al, 2000). One possible explanation for this discre-
pancy might be that, in contrast to the study mentioned, we
have analysed paired tissue samples, i.e. non-malignant and
tumorigenic tissue originating from the same individual. Further-
more, the tumour speciﬁc increase in rac1 mRNA expression
reported in this study was rather low (i.e. *50%) (Schnelzer et
al, 2000) and does not reﬂect the large increase in Rac1 protein
expression observed in the tumours. This fact again is in line with
our own data. In addition, we show that expression of the rac1
splice variant rac1b, which was shown to be enhanced in colorectal
tumours (Jordan et al, 1999), is not tumour-speciﬁc increased in
breast tissue. Regarding rac1b, our data corroborate the study of
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(6), 635–644Schnelzer et al (2000). Altogether our results strongly indicate that
the drastic differences in Rho protein levels between malignant and
non-malignant breast tissue are not due to changes in expression of
the corresponding rho mRNAs. Thus, obviously, differences in gene
expression do not account for the observed tumour speciﬁc
increase in Rho proteins. We also analysed the stability of Rho
proteins in the breast carcinoma cell line MCF-7 upon inhibition
of protein synthesis by cycloheximide/anisomycin. These experi-
ments showed no signiﬁcant changes in Rho protein level up to
10 h after blockage of protein synthesis (data not shown). This
indicates that Rho proteins are highly stable, undergoing a very
slow turnover. Therefore, although we can not completely rule
out the possibility that Rho proteins are rapidly degraded under
in vivo conditions in normal breast tissue but not in tumours, it
appears more likely that differences in protein stability are not
responsible for the elevated level of Rho GTPases observed in
breast tumours. We hypothesise that translational control mechan-
isms are involved in the upregulation of the amount of Rho
protein in tumours.
The data also revealed broad interindividual variations in the
expression of rho mRNAs both in normal and tumorigenic tissues.
The same is true for Rho protein expression in tumours (in
normal tissue Rho protein level was in general below the detec-
tion limit). In contrast to Rho GTPases, the interindividual
variability in the expression of Rho-GDI and especially ERK2
protein was very low in the tumour fraction. That is why we used
ERK2 protein as internal reference for calculating the relative
amount of Rho protein (i.e. Rho protein level/ERK2 protein
level). Correlating relative Rho protein expression with various
clinical parameters we found that the level of RhoA-like GTPases
signiﬁcantly increases with histological grade as well as with the
proliferation index (MIB-1) of the tumours. Interestingly, the
expression of Rac1, which is discussed to be the Rho GTPase
most important for cell–cell and cell–ECM adhesion (Price
and Collard, 2001) as well as for lamellipodia formation (Hall,
1998) correlates with histological grading only in case of progres-
sion from grade I to grade II, but not to grade III. One possible
interpretation of this ﬁnding is that Rac function might be impor-
tant only during early steps in tumour progression, but not in
later steps. It is also possible that Rac activity is modulated in
tumours by changes in the activity of regulatory factors such as
guanine exchange factors (GEFs). In this case, Rac protein levels
would remain unchanged. Therefore, future studies addressing
the question of expression level and activity of Rho-regulatory
factors in breast tumours are required. A correlation between
RhoA-like protein expression and the amount of the HER-2/neu
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Figure 8 Relationship between rho mRNA expression and histological grade of breast tumours. (A) Representative analysis of rho mRNA expression (i.e.
rhoA, rhoB, rhoC, rac1) in breast tumours of WHO grade I and III, respectively. As internal control mRNA expression of GDH and Ki-Ras was determined. (B)
Correlation analysis of rho mRNA expression and grading status of breast tumours. Relative rho mRNA expression was determined by referring rho mRNA
levels to that of GDH mRNA. 1,2,3; grade I, II and III, respectively.
Table 2 Mutational analysis of Rho in breast tumours. Sequence analysis
of Rho GTPases in malignant and normal human breast tissues. Nucleotides
encoding amino acids up to position 95 were subjected to sequence ana-
lysis. This region of Rho GTPases covers their GTP binding and effector
binding domains
Rho GTPase
Samples analysed
(tumour/normal tissue)
Mutational changes detected*
(tumour/normal tissue)
RhoA 11/3 0/0
RhoB 11/3 0/0
RhoC 10/3 0/0
Rac1 9/3 0/0
*Indicated are the amino acid exchanges as based on the corresponding Rho protein
sequences published in Embl database.
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British Journal of Cancer (2002) 87(6), 635–644 ã 2002 Cancer Research UKoncogene or p53 mutation was not observed. The same is true for
RhoA expression and hormone status of the tumours (data not
shown). Summarising the data, a good correlation with clinically
established tumour markers was observed with RhoA-like proteins
but not with Rac1 and Cdc42. Although the amount of Rho
proteins in tumours was not related to their mRNA levels, we
analysed whether mRNA expression of particular rho mRNA
species might be independently related to the histological grade
of breast tumours. This correlation analysis was performed since
(1) about 30% of the tumours investigated showed enhanced
expression of rhoB and rhoC mRNA and (2) in a recent report
it has been shown that rhoC mRNA expression is related to
malignancy of pancreas carcinomas (Suwa et al, 1998b). Unfortu-
nately, studies on the level of protein expression were not
included in this report. Therefore the question remains whether
or not the reported increase in rhoC mRNA is accompanied by
elevation in the amount of Rho protein. For breast tumours we
found that there was only a tendency in the expression of rhoB,
rhoC and rac1 mRNA, but not of rhoA mRNA, to increase with
grading. The tendency was most obvious for rhoC. However,
because of the tremendous variability of rhoC mRNA expression
in grade III tumours, a statistically signiﬁcant correlation as found
on the level of the protein expression was not observed. Thus, in
contrast to pancreas carcinomas, rhoC mRNA expression level
seems not to be an indicator of malignancy in breast tumours.
Since Ras is often either overexpressed or mutationally activated
in a variety of human tumours, we wished to know whether the
Ras-homologous GTPases are mutationally altered in breast
tumours. Sequence analyses of the RhoA-like GTPases RhoA, RhoB
and RhoC as well as of Rac1 failed to detect any mutations within
the GTP binding or the effector binding domains of these Rho
GTPases. Obviously, tumour associated changes in Rho-regulated
functions are independent of mutational changes of Rho proteins
itself. Rather, overexpression seems to be the predominant trait
of activation of Rho signalling in breast tumours. Whether or
not alterations in the activity of Rho-regulatory factors or Rho
effector proteins such as Rho-kinase (ROK) or p21-associated
kinases (PAK) do also occur in breast tumours will be subject of
forthcoming studies.
In summary, we demonstrated that different types of Rho
GTPases are highly overexpressed on protein but not on mRNA
levels in breast tumours as compared to the normal tissue of the
same individual. The data show at the ﬁrst time that the amount
of RhoA-like proteins but not of Rac1 and Cdc42, is related to
clinically established prognostic breast tumour markers such as
histological grade and proliferation index. A signiﬁcant correlation
between the expression of RhoA-like GTPases and histological
grade was only observed on the protein, but not on the mRNA
level. Overall, the data support the view that RhoA-like proteins
are important factors involved in the development and progression
of breast tumours and are of prognostic value. Moreover, the data
may provide a platform for the development of novel tumour ther-
apeutic strategies which are based on the inhibition of RhoA-like
GTPases.
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